Contrasting Cellectis (CLLS) & Its Competitors

Cellectis (NASDAQ:CLLS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Cellectis to related businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Cellectis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Cellectis Competitors	-9,054.29%	-198.66%	-30.54%

Institutional and Insider Ownership

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Cellectis and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cellectis	$56.58 million	-$67.59 million	-1.70
Cellectis Competitors	$722.78 million	$12.25 million	-9.92

Cellectis’ peers have higher revenue and earnings than Cellectis. Cellectis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Cellectis has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Cellectis’ peers have a beta of 1.14, suggesting that their average share price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cellectis and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2	2	2	1	2.29
Cellectis Competitors	9774	15037	45265	1571	2.54

Cellectis currently has a consensus target price of $5.46, suggesting a potential upside of 394.12%. As a group, “Biotechnology” companies have a potential upside of 98.97%. Given Cellectis’ higher possible upside, research analysts plainly believe Cellectis is more favorable than its peers.

Summary

Cellectis beats its peers on 9 of the 13 factors compared.

Cellectis Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.